Tiziana's Intranasal Anti-CD3 Therapy Shows Promise in Long COVID Neuroinflammation
Event summary
- Tiziana Life Sciences published preclinical data showing intranasal anti-CD3 antibody foralumab reduces neuroinflammation and improves cognitive function in Long COVID mouse models.
- Study conducted by researchers from Yale University and Harvard Medical School demonstrated increased brain regulatory T cells, reprogrammed microglia, and restored neurogenesis.
- Human observational data showed Long COVID patients with neurological symptoms exhibit lower circulating Treg levels.
- Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development, currently in trials for non-active secondary progressive multiple sclerosis.
The big picture
Tiziana's findings position foralumab as a potential non-invasive treatment for Long COVID's neurological symptoms, expanding its pipeline beyond multiple sclerosis. The study's demonstration of efficacy in both early and chronic phases of infection suggests a broad therapeutic window, which could be attractive for other post-viral neuroinflammatory conditions. The company's focus on intranasal delivery differentiates it from traditional intravenous immunotherapies, potentially offering better safety and tolerability.
What we're watching
- Clinical Translation
- How quickly Tiziana can transition from preclinical success to human trials for Long COVID indications.
- Competitive Positioning
- Whether foralumab's unique delivery mechanism and fully human antibody status can differentiate it in the neuroinflammatory disease space.
- Regulatory Pathway
- The pace at which regulatory approvals might progress given the broad therapeutic potential indicated by these findings.
Related topics